rovelizumab also known leukarrest humanized monoclonal antibody experimental immunosuppressive drug rovelizumab developed icos treat patients haemorrhagic drug monoclonal antibody suppresses white blood cells become overly active testing number patients given drug low rovelizumab delivered within four hours injury consent often patient unconscious relatives reached give june icos many medical centers asked united states food drug administration fda waive consent requirements situations patient high risk dying relatives could medical ethicists opposed waiving consent fda approved proposal august five medical development rovelizumab halted april interim data phase iii clinical trials meet icoss companys goals rovelizumab included reducing chance multiple organ failure reducing deathrate shock rovelizumab also tested treating heart attack multiple sclerosis stroke explored treatment cerebral vasospasm head trauma kidney transplantation multiple companies tried develop drugs none among genentechs erlizumab two drugs developed protein design labs although trials humans gone well research drugs animals thought experimental medicines affecting lymphocyte adhesion pathway humans unintended immune activation dostarlimab ibalizumab httpsenwikipediaorgwikirovelizumab